(2024). The Most Recommended Site for Subcutaneous Remodulin® (Treprostinil) Pump to Minimize Patient Pain. test, 8(2), -. doi: 10.21608/cvrepj.2024.400099
. "The Most Recommended Site for Subcutaneous Remodulin® (Treprostinil) Pump to Minimize Patient Pain". test, 8, 2, 2024, -. doi: 10.21608/cvrepj.2024.400099
(2024). 'The Most Recommended Site for Subcutaneous Remodulin® (Treprostinil) Pump to Minimize Patient Pain', test, 8(2), pp. -. doi: 10.21608/cvrepj.2024.400099
The Most Recommended Site for Subcutaneous Remodulin® (Treprostinil) Pump to Minimize Patient Pain. test, 2024; 8(2): -. doi: 10.21608/cvrepj.2024.400099

The Most Recommended Site for Subcutaneous Remodulin® (Treprostinil) Pump to Minimize Patient Pain

Cardiovascular Research Prove Journal
Volume 8, Issue 2, December 2024    PDF (1.23 M)
Document Type: Abstracts
DOI: 10.21608/cvrepj.2024.400099
Abstract
The first Remodulin® I-jet pump implantation in 
Egypt was performed in 2017 at the Magdy 
Yacoub Aswan Heart Centre. Face flushing, 
headaches, jaw pain, cramping, diarrhea, and pain 
at the insertion site are major side effects of the 
drug. According to clinical studies, site pain 
reaches up to 93% of patients with Remodulin® 
pump. Some patients at Aswan Heart Center want 
to discontinue the treatment because of the intense 
pain
Statistics
Article View: 76
PDF Download: 59